• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

FTC Weighs Merger's Impact on Specialty Drugs

Article

Medco Health Solutions

MHS

+0.22%

Express Scripts

ESRX

-0.20%

The Federal Trade Commission is taking a hard look at whether the proposed $29 billion merger of prescription-drug benefit managers Inc. and Inc. would impede patients' access to expensive drugs used to treat cancer and certain other life-threatening diseases.

FTC commissioners, including Chairman Jon Leibowitz, have asked many questions about the market for the so-called specialty drugs in meetings with industry groups and others, according to people who have attended the meetings. The questions have involved the relationship between PBMs, which administer prescription-drug coverage for employers and insurers, and the manufacturers of the drugs, these people said.

Read the full story: http://hcp.lv/HkWV2o

Source: The Wall Street Journal

Related Videos
Joshua K. Sabari, MD< NYU Langone Perlmutter Cancer Center
Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"
Imran Khan, MD, PhD, Johnson & Johnson
ateyeh soroush
dr kathy zackowski
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.